Capricor Therapeutics
CAPR
132 hedge funds and large institutions have $791M invested in Capricor Therapeutics in 2025 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 44 increasing their positions, 38 reducing their positions, and 24 closing their positions.
660% more capital invested
Capital invested by funds: $104M → $791M (+$687M)
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
88% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 24
28.36% more ownership
Funds ownership: 31.62% → 59.98% (+28%)
16% more call options, than puts
Call options by funds: $132M | Put options by funds: $114M
16% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 38
15% more funds holding
Funds holding: 115 → 132 (+17)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$23.3M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$22.5M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$22.2M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$19.7M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$11.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$3.93M |
| 2 |
PC
Pier Capital
Stamford,
Connecticut
|
-$3.58M |
| 3 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$3.32M |
| 4 |
BDF
Black Diamond Financial
Towson,
Maryland
|
-$2.59M |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.55M |
CAPR Hedge Fund Activity: Q4 2025 in Review
132 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q4 2025, worth a combined $791M — up 660% from $104M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new CAPR positions and 24 closed out — a net gain of 21 holders — while 44 added to existing stakes and 38 trimmed.
The largest buyer was Suvretta Capital Management, opening a new position worth an estimated $23.3M. The largest seller was Two Sigma Investments, cutting an estimated $3.93M.
- 132 institutional investors held Capricor Therapeutics (CAPR) as of Q4 2025, up from 115 in Q3 2025.
- Funds reported $791M of Capricor Therapeutics stock for Q4 2025, up 660% quarter-over-quarter.
- 45 funds opened new Capricor Therapeutics positions in Q4 2025 and 24 closed out, a net change of +21 holders.
- The largest Capricor Therapeutics buyer in Q4 2025 was Suvretta Capital Management, an estimated $23.3M added.
- The largest Capricor Therapeutics seller in Q4 2025 was Two Sigma Investments, an estimated $3.93M sold.
Based on aggregated 13F filings for Q4 2025.